Short interest for Actinium Pharma gives investors a sense of the degree to which investors are betting on the decline of Actinium Pharma's stock. Short interest data is updated every two weeks.

Actinium Pharma Stock (AMEX:ATNM), Short Interest Report

Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer

Biotech

Interview

General

ATNM

Sandesh Seth, CEO &amp; Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access.

News

Movers

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or refractory

What&#39;s Going On With Actinium Pharmaceuticals Stock?

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

APLS

ARBE

BBIG

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

EBET

IBIO

MDXH

NEXI

OKYO

OWLT

SGML

SPRC

SRNE

TRKA

VLON

ZDGE

Gainers


	Troika Media Group Inc  (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday.


Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

<ul>
<li>Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern and Principal Investigator for the trial to join Actinium management for webinar</li>
<li>Expansion of Iomab-ACT program with commercial CAR-T supported by ongoing MSKCC clinical trial with success implying a potential billion-dollar market opportunity in lymphodepletion</li>
<li>Webinar to be held on Monday, May 20th at 8:00 AM ET</li>
</ul>
<p>NEW YORK, May 7, 2024 /PRNewswire/ -- <strong>Actinium Pharmaceuticals, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL call on Monday, May 20, 2024, at 8:00 AM ET to provide updates and highlight its recently announced clinical trial to study Iomab-ACT with a leading FDA approved CAR-T cell therapy at the University of Texas Southwestern (UTSW). Iomab-ACT is an ARC that targets CD45, a marker expressed on blood cancer cells and immune cells that is intended to enable conditioning prior to cell and gene therapies such as CAR T-cell therapy and replace the non-targeted chemotherapy that is currently used for conditioning. There are six CAR-T cell therapies approved to treat patients with leukemias, lymphomas and multiple myeloma that collectively reached sales in 2023 exceeding $3.5 billion.</p>
<p>Dr. Farrukh Awan specializes in the treatment of patients with leukemia and lymphoma including CAR-T therapy and bone marrow transplantation. Dr. Awan will serve as principal investigator for this study that will be led by UTSW.</p>
<p>To date, Iomab-ACT has been studied in a clinical trial with an investigational CD19 targeting CAR-T cell therapy developed by Memorial Sloan Kettering Cancer Center (MSKCC) under a National Institutes of Health funded grant. The trial at UTSW will be the first trial to study Iomab-ACT or any targeted radiotherapy conditioning agent with an FDA approved CAR-T therapy.</p>
<p>Registration for the KOL webinar can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4159695-1&amp;h=1562083725&amp;u=https%3A%2F%2Flifescievents.com%2Fevent%2Factinium%2F&amp;a=here">here</a> or on the investor relations page of Actinium's website <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4159695-1&amp;h=5570792&amp;u=https%3A%2F%2Fir.actiniumpharma.com%2Fir-calendar&amp;a=here">here</a>.</p>
<p><strong>Iomab-ACT Phase 1 CAR-T Conditioning Results</strong></p>
<p>Actinium presented results from its ongoing phase 1 trial using Iomab-ACT as conditioning prior to CD19 CAR-T therapy for patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) or Diffuse Large B-cell Lymphoma (DLBCL) at the Tandem Meetings I&nbsp;Transplantation &amp; Cellular Therapy Meetings of ASTCT and CIBMTR the combined annual meetings of the&nbsp;American Society for Transplantation and Cellular Therapy (ASTCT)&nbsp;and the Center for International Blood &amp; Marrow Transplant Research (CIBMTR) in February 2024. Importantly, no patients (0/4) developed immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade, a major safety measure of the study and minimal Cytokine Release Syndrome (CRS). ICANS is observed in 25% or more of pts w/ R/R B-ALL and DLBCL treated with various currently approved CAR T-cell products. Iomab-ACT demonstrated transient depletion of peripheral blood lymphocytes and monocytes. Persistence of CAR T-cells up to 8 weeks and minimal non-hematologic toxicities have been observed to date.</p>


Actinium Announces KOL Webinar To Highlight Recently Announced Iomab-ACT Trial With Leading FDA Approved Commercial CAR T-Cell Therapy Being Led By The University Of Texas Southwestern

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $50 price target.</p>


Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target

<p>Cantor Fitzgerald  analyst Kristen Kluska   reiterates Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Overweight and maintains $21 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price Target

<p>--&nbsp;Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active relapsed or refractory acute myeloid leukemia</p>
<p>-- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an&nbsp;Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002)</p>
<p>NEW YORK, April 18, 2024 /PRNewswire/ -- <strong>Actinium Pharmaceuticals, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 50th Annual European Bone Marrow Transplant Society Meeting (EBMT) held in Glasgow, Scotland on April 14-17. The results showed that an Iomab-B led bone marrow transplant (BMT) results in higher rates of remissions and durable Complete Remission (dCR), which is the primary endpoint of the SIERRA trial, as well as significant improvement in overall survival in TP53 positive patients. Iomab-B is a targeted radiotherapeutic comprised of an anti-CD45 monoclonal antibody with the Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients age 55 and above with active relapsed or refractory acute myeloid leukemia (AML) and compared outcomes of patients receiving Iomab-B BMT to those of patients receiving physician's choice of care in the control arm. In total, 24% (37/153) of the patients enrolled on SIERRA had a TP53 mutation, which is associated with limited treatment options and poor outcomes.</p>
<p>Data highlighted in the ASH oral presentation, which can be accessed on the investor relations page of Actinium's website, included:</p>
<p><strong>Response rates by TP53 Mutation Status:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"><br /><br />&nbsp;</td>
<td colspan="1" rowspan="1"><strong>Iomab-B &amp; Crossover</strong></td>
<td colspan="1" rowspan="1"><strong>Control Arm</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1">TP53 Positive</td>
<td colspan="1" rowspan="1"><strong>N=27</strong></td>
<td colspan="1" rowspan="1"><strong>N=10</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>CR</strong></td>
<td colspan="1" rowspan="1"><strong>55.56% (15/27)</strong></td>
<td colspan="1" rowspan="1"><strong>0&nbsp;%</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>dCR</strong></td>
<td colspan="1" rowspan="1"><strong>14.81% (4/27)</strong></td>
<td colspan="1" rowspan="1"><strong>0&nbsp;%</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1">TP53 Wildtype</td>
<td colspan="1" rowspan="1"><strong>N=93</strong></td>
<td colspan="1" rowspan="1"><strong>N=23</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>CR</strong></td>
<td colspan="1" rowspan="1"><strong>58.06% (54/93)</strong></td>
<td colspan="1" rowspan="1"><strong>17.39% (4/23)</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>dCR</strong></td>
<td colspan="1" rowspan="1"><strong>16.13% (15/93)</strong></td>
<td colspan="1" rowspan="1"><strong>0&nbsp;%</strong></td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p><strong>Overall Survival in Patients with a TP53 Mutation:</strong></p>
<p><figure class="table"><br />
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"><br /><br />&nbsp;</td>
<td colspan="1" rowspan="1"><strong>Iomab-B &amp; Crossover</strong></td>
<td colspan="1" rowspan="1"><strong>Control Arm</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Median OS</strong></td>
<td colspan="1" rowspan="1">5.49 months</td>
<td colspan="1" rowspan="1">1.66 months</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Number of Patients</strong></td>
<td colspan="1" rowspan="1">27</td>
<td colspan="1" rowspan="1">10</td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>Hazard Ratio</strong></td>
<td colspan="2" rowspan="1"><strong>0.23</strong></td>
</tr>
<tr>
<td colspan="1" rowspan="1"><strong>p-value</strong></td>
<td colspan="2" rowspan="1"><strong>0.0002</strong></td>
</tr>
</tbody>
</table>
<p></p></figure>
</p><p>Median OS was 6.37 months in TP53 negative patients receiving Iomab-B and 5.72 months for TP53 positive patients demonstrating Iomab-B's ability to overcome TP53 gene mutations.</p>
<p>Dr. Hannah Choe, Assistant Professor of Medicine at Ohio State University and SIERRA trial investigator, commented, "TP53 mutations are associated with very poor&nbsp;outcomes due to resistance to anti-leukemic therapies with patients rarely offered access to potentially curative transplantation. The SIERRA trial showed that Iomab-B was well tolerated and can enable unprecedented access to transplant in this patient population and induce high complete remission rates despite active, relapsed/refractory disease and a TP53 mutation. These results were very well received at EBMT and demonstrate the novelty and safety of a CD45-directed antibody radiation conjugate. More importantly, we see that these response rates translated into improved overall survival, overcoming the increased risk associated with TP53 mutation while no other viable treatment options exist. We are excited for Iomab-B's potential use and safety for disease control in patients with a TP53 mutation."</p>


Actinium Highlights Ability Of Iomab-B To Overcome High-Risk TP53 Mutation Resulting In Improvement In Overall Survival In Patients With Active Relapsed Refractory AML At The European Bone Marrow Transplant Annual Meeting

<p>-&nbsp; The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis</p>
<p>-&nbsp; Represents the eleventh oral presentation of the Phase 3 SIERRA results demonstrating continued recognition of the high potential for Iomab-B led allogeneic bone marrow transplant by the bone marrow transplant community&nbsp;&nbsp;</p>
<p>NEW YORK, April 1, 2024 /PRNewswire/ --<strong> Actinium Pharmaceuticals, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 – 17, 2024, in Glasgow, Scotland. Iomab-B is a targeted radiotherapy conditioning agent comprised of an anti-CD45 monoclonal antibody and Iodine-131 radioisotope payload. The Phase 3 SIERRA trial enrolled 153 patients with active relapsed or refractory acute myeloid leukemia (r/r AML) and compared outcomes of patients receiving Iomab-B and a bone marrow transplant (BMT) to those of patients receiving physician's choice of care in the control arm. In total, 24% of patients (37/153) in the SIERRA trial had a TP53 mutation, which is associated with poor outcomes, and 27 of the TP53 positive patients received Iomab-B. Iomab-B met the primary endpoint of durable Complete Remission (dCR) in the SIERRA trial with high-statistical significance (p&lt;0.0001) and 100% of patients receiving a therapeutic dose of Iomab-B achieved BMT access and engagement.</p>
<p>&nbsp;</p>
<p>Dr. Hannah Choe, Assistant Professor of Medicine at Ohio State University and SIERRA trial investigator will present the SIERRA results. Details of the oral presentation are as follows:</p>
<p><strong>Title</strong>: I-131-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Demonstrates Survival Benefit and Overcomes High-Risk TP53 Mutations in Patients with R/R AML</p>
<p><strong>Date and Time</strong>: Wednesday, April 17, 2024, 12:39 PM GMT</p>
<p><strong>Session: </strong>OS17-02</p>
<p><strong>Location</strong>: Scottish Event Campus (SEC Centre)</p>
<p>Dr. Avinash Desai, Actinium's Chief Medical Officer, said, "In addition to demonstrating unprecedented 100% access to BMT in Iomab-B treated patients with active r/r AML and achieving the primary endpoint of dCR with high statistical significance, we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial. We look forward to returning to EBMT and once again highlighting the positive results from the Phase 3 SIERRA trial to the European bone marrow transplant community. We are particularly focused on Europe as it represents the largest bone marrow transplant market performing 40% of the BMT transplants globally. We also look forward to continuing to work with our European, Middle East and North African commercial partner, Immedica Pharma Ab, to bring Iomab-B to patients globally."</p>
<p><strong>About the EBMT Annual Meeting</strong></p>
<p>The Annual Meeting of the EBMT is attended by more than 5,500 participants, including physicians, nurses, data managers, statisticians, quality managers, cell therapists, paediatricians, pharmacists, psychologists, psychiatrists and psychoanalysts, transplant coordinators, lab scientists, trainees, patients. This important congress ensures and encourages dialogues and information exchange, education and scientific productivity.</p>
<p>The full annual meeting program is available online at:<br /><br /><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4129932-1&amp;h=4087646405&amp;u=https%3A%2F%2Febmt2024.abstractserver.com%2Fprogram%2F%23%2Fprogram%2F2%2Fhorizontal&amp;a=https%3A%2F%2Febmt2024.abstractserver.com%2Fprogram%2F%23%2Fprogram%2F2%2Fhorizontal">https://ebmt2024.abstractserver.com/program/#/program/2/horizontal</a>.</p>


Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual Meeting

<p><strong>Actinium Pharmaceuticals, Inc.</strong>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that the&nbsp;University of Texas Southwestern Medical Center&nbsp;(UT Southwestern) will lead a clinical trial studying Actinium&#39;s Iomab-ACT, a targeted radiotherapy conditioning agent prior to patients receiving an FDA approved commercial CAR T-cell therapy. UT Southwestern will start recruiting patients following FDA&#39;s review and clearance of the study. CAR T-cell therapy utilizes patients&#39; own immune cells called T-cells, which are engineered to include a chimeric antigen receptor and then reinfused into the patient to recognize and destroy cancer cells. Currently, there are six CAR-T therapies approved to treat patients with leukemias, lymphomas and multiple myeloma that collectively reached sales in 2023 exceeding&nbsp;$3.5 billion.</p>


Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

<p>Maxim Group  analyst Jason McCarthy   maintains Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and raises the price target from $20 to $30.</p>


Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30

Watching Actinium Pharmaceuticals; HC Wainwright: First Take Says 'Appetite Remains High For Radiopharmaceuticals; We See Actinium As Ripe For Takeout And Believes It Is Receiving M&A Interest'

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   maintains Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) with a Buy and maintains $50 price target.</p>


HC Wainwright & Co. Maintains Buy on Actinium Pharma, Maintains $50 Price Target

Actinium Pharmaceuticals Disclosed The Launch Of Strategic Initiative Focused On The Manufacture Of The Highly Sought After Medical Isotope Actinium-225 (Ac-225)

Health Care

Actinium Pharmaceuticals Has Launched A Strategic Initiative Focused On The Manufacture Of Medical Isotope Actinium-225 Leveraging Its Propriety Cyclotron-based Method

Actinium Announces Iomab-B Markedly Increases Long-term Survival In Older Patients With Active Relapsed/Refractory Acute Myeloid Leukemia In Phase 3 SIERRA Trial At 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings Of ASTCT And CIBMTR

Actinium Highlights Improved Survival With Iomab-B In TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients In SIERRA Trial And Other Presentations At 2024 Transplantation & Cellular Therapy Meetings of ASTCT And CIBMTR

<h3>Gainers</h3>
<ul>
<li><strong>Singular Genomics Sys</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMIC#NASDAQ">OMIC</a>) shares moved upwards by 17.9% to $0.66 during Friday's after-market session. The market value of their outstanding shares is at $48.4 million. </li>
<li><strong>Vaccinex</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock increased by 11.61% to $0.77. The company's market cap stands at $9.6 million. </li>
<li><strong>Celularity</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 7.52% to $0.46. The market value of their outstanding shares is at $99.5 million. </li>
<li><strong>ZyVersa Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock rose 6.87% to $0.62. The company's market cap stands at $1.0 million. </li>
<li><strong>BioXcel Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) stock moved upwards by 5.21% to $2.22. The company's market cap stands at $66.4 million. </li>
<li><strong>Turnstone Biologics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) shares rose 4.62% to $2.26. The market value of their outstanding shares is at $52.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Intelligent Bio Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock declined by 15.8% to $5.7 during Friday's after-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li><strong>Perspective Therapeutics</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock fell 8.9% to $0.82. The company's market cap stands at $405.5 million. </li>
<li><strong>NanoString Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock decreased by 7.83% to $0.21. The market value of their outstanding shares is at $10.2 million. </li>
<li><strong>Bone Biologics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares declined by 6.36% to $3.83. The company's market cap stands at $2.0 million. </li>
<li><strong>Actinium Pharma</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) stock decreased by 4.95% to $5.19. The market value of their outstanding shares is at $144.0 million. </li>
<li><strong>Biolase</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock declined by 4.94% to $0.48. The company's market cap stands at $1.6 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BBLG

BIOL

BTAI

CATX

CELU

Intelligent Bio Solutions Inc. - Common Stock

INBS

NSTG

OMIC

TSBX

VCNX

ZVSA

12 Health Care Stocks Moving In Friday's After-Market Session

<p><a href="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11844799" title="https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11844799">https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11844799</a></p>


Actinium Pharmaceuticals Granted U.S. Patent #11844799:  Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Kiora Pharmaceuti...

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) an...

Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)

Maxim Group analyst Jason McCarthy has maintained their bullish stance on ATNM stock, giving a Buy rating on April 1. Jason McCarthy has given his ...

Actinium Pharmaceuticals: Strong Buy Rating on Financial Health and Promising Pipeline

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result. And poor results can happen to anybody, big or small.</p>



<p>Indeed, the prospect of being on the wrong end of a giant killing adds significant risk to market participants. So, as a calculated approach, since you&rsquo;re going to be taking huge risks anyways, you might as well go for ideas with the substantial upside return potential. On that note, below are under-$10 biotech stocks to consider.</p>



<h2>Actinium Pharmaceuticals (ATNM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p>Based in New York, <strong>Actinium Pharmaceuticals</strong> (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/atnm-stock-quote/"><strong>ATNM</strong></a>) is a clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/quote/ATNM/profile">developing targeted radiotherapies</a>. Specifically, it delivers cancer-killing radiation to treat patients with high unmet medical needs. Actinium features a product candidate which is in Phase 3 clinical trials for elderly relapsed or refractory acute myeloid leukemia.</p>



<p>Currently, Wall Street analysts rate ATNM a <a href="https://www.tipranks.com/stocks/atnm/forecast">unanimous strong buy</a>. Their average price target stands at $30.50, implying nearly 239% upside potential. Notably, the high-side estimate calls for a price of $50. Among the covering experts, they&rsquo;re anticipating fiscal 2024 loss per share to land at $1.73. Though not profitable, this forecast represents an improvement over last year&rsquo;s loss of $1.83.</p>



<p>At the moment, Actinium is practically a pre-revenue enterprise. If we want to dive into the minutia, it did post sales of $81,000 last year. However, it&rsquo;s not projected to generate any sales this year. However, in fiscal 2025, analysts are looking for sales of $72.82 million. Therefore, it&rsquo;s one of the more promising ideas for under-$10 biotech stocks to consider.</p>



<h2>Outlook Therapeutics (OTLK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/eyes-stock-1-300x169.png" alt="Image of a woman with a digital display over her eye."><div>Source: Who is Danny / Shutterstock.com</div></div><p>Headquartered in Iselin, New Jersey, <strong>Outlook Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/otlk-stock-quote/"><strong>OTLK</strong></a>) operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate, <a href="https://ir.oncobiologics.com/news-releases/news-release-details/outlook-therapeuticsr-receives-european-union-positive-chmp#:~:text=ONS%2D5010%2FLYTENAVA%E2%84%A2%20is,AMD%20and%20other%20retinal%20diseases.">ONS-5010 for the treatment of wet age-related macular degeneration</a> and other retina diseases is currently in Phase 3 clinical trials.</p>



<p>Presently, Wall Street rates OTLK a <a href="https://www.tipranks.com/stocks/otlk/forecast">unanimous strong buy</a>. Further, the average price target lands at $40.20, implying 362% growth potential. Moreover, the highest price target hits $60, emphasizing the broad enthusiasm for this biotech firm. For fiscal 2024, experts see the company posting a loss per share of $3.28. Yes, it&rsquo;s in the red but it&rsquo;s an improvement over last year&rsquo;s $4.80 below breakeven.</p>



<p>However, the top line is where things get exciting. Analysts see revenue reaching $240,000, with the high-side estimate hitting $1.43 million. Last year, Outlook did not generate any sales. Even better, forecasts call for fiscal 2025 sales to hit $13.09 million. Thus, it&rsquo;s a compelling idea for under-$10 biotech stocks.</p>



<h2>Recursion Pharmaceuticals (RXRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/rxrx1600-300x169.png" alt="Recursion Pharmaceuticals (RXRX) website displayed on a modern smartphone"><div>Source: Piotr Swat / Shutterstock.com</div></div><p>A clinical-stage biotech firm, <strong>Recursion Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/"><strong>RXRX</strong></a>) engages in integrating technological innovations across biology, automation, data science and engineering to industrialize drug discovery. One of its lead product candidates, a therapeutic for treating cerebral cavernous malformation, is currently in Phase 2 clinical trials.</p>



<p>Per analysts, RXRX stock represents a <a href="https://www.tipranks.com/stocks/rxrx/forecast">moderate buy</a>. Further, the average price target lands at $17, implying over 102% upside potential. For the current fiscal year, experts anticipate Recursion to post a loss per share of $1.72. Admittedly, that&rsquo;s worse than last year&rsquo;s red ink of $1.58. That said, the most optimistic assessment calls for a loss of $1.49.</p>



<p>On the top line, the news becomes substantially more favorable. Analysts are looking for sales of $56.16 million,. That would be up 26% from last year&rsquo;s tally of $44.58 million. For fiscal 2025, they&rsquo;re looking for revenue of $88.43 million, up 57.5% against projected 2024 sales. If you like to speculate, RXRX belongs on your radar of under-$10 biotech stocks to buy.</p>



<h2>Ocular Therapeutix (OCUL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/12/eye-1600-300x169.jpg" alt="A close-up of someone's eye"><div>Source: Shutterstock</div></div><p>Headquartered in Bedford, Massachusetts, <strong>Ocular Therapeutix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocul-stock-quote/"><strong>OCUL</strong></a>) is a biopharma company focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye. It uses a bioresorbable hydrogel-based formulation technology. It&rsquo;s developing an <a href="https://www.ophthalmologytimes.com/view/ocular-therapeutix-inc-screens-first-3-patients-in-phase-3-sol-1-trial">axitinib intravitreal implant that is in Phase 3 trials</a> for the treatment of wet age-related macular degeneration.</p>



<p>Per Wall Street analysts, OCUL rates as a <a href="https://www.tipranks.com/stocks/ocul/forecast">consensus strong buy</a>. On average, the price target stands at $16.33, implying over 104% upside potential. Further, the most optimistic target calls for a price of $24. Covering experts see fiscal 2024&rsquo;s loss per share coming in at 83 cents. While not a profitable enterprise, this figure would represent a conspicuous improvement over last year&rsquo;s loss of $1.02.</p>



<p>On the top line, analysts anticipate revenue to hit $68.34 million. If so, we&rsquo;re talking about year-over-year growth of 16.9% from last year&rsquo;s haul of $58.44 million. For fiscal 2025, they&rsquo;re looking for sales of $85.9 million. Even better, the highest target seeks a top-line print of $116 million. Overall, it&rsquo;s a compelling take for under-$10 biotech stocks.</p>



<h2>Marinus (MRNS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p>Based in Radnor, Pennsylvania, <strong>Marinus</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrns-stock-quote/"><strong>MRNS</strong></a>) is a pharmaceutical company focusing on the development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. Its <a href="https://ir.marinuspharma.com/news/news-details/2024/Marinus-Pharmaceuticals-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2023-ZTALMY-Net-Product-Revenue-and-Provides-Business-Update/default.aspx">main product is Ztalmy</a>, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations.</p>



<p>Presently, covering experts rate MRNS stock as a <a href="https://www.tipranks.com/stocks/mrns/forecast#">consensus strong buy</a>. The average price target lands at $19.78, implying 163% growth potential. Also, the highest target calls for a price per share of $28. For the current fiscal year, analysts are looking for a loss per share of $2.36. While the bottom line is printed in red ink, the projected figure would be an improvement over last year&rsquo;s loss of $2.63 per share.</p>



<p>On the top line, analysts are looking for revenue of $40.53 million. That would imply YOY growth of nearly 31% from last year&rsquo;s haul of $30.99 million. Further, the most optimistic target seeks a sales print of $54.3 million. For fiscal 2025, revenue could rise to $66.62 million. Based on the growth potential, MRNS is one of the under-$10 biotech stocks to consider.</p>



<h2>Fulcrum Therapeutics (FULC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/medical-biotech-stocks1600-300x169.png" alt="Healthcare business graph data and growth, Medical examination and doctor analyzing medical report network connection on tablet screen. VANI stock"><div>Source: PopTika / Shutterstock.com</div></div><p>Calling Cambridge, Massachusetts home, <strong>Fulcrum Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/fulc-stock-quote/"><strong>FULC</strong></a>) is a clinical-stage biopharma focusing on the development of products for improving the lives of patients suffering from genetically defined diseases. In particular, it seeks to address conditions with high unmet medical needs. It features a small-molecule-based candidate that&rsquo;s in Phase 3 trials for the treatment of muscular dystrophy.</p>



<p>Presently, Wall Street analysts rate FULC a <a href="https://www.tipranks.com/stocks/fulc/forecast">consensus strong buy</a> with a $13.29 average price target. That implies over 77% upside potential. Further, the most optimistic forecast calls for a price per share of $17. For fiscal 2024, covering experts are anticipating a loss per share of $1.75. Admittedly, that&rsquo;s an expansion of last year&rsquo;s red ink of $1.59 per share.</p>



<p>It also doesn&rsquo;t immediately get better on the top line, with analysts projecting sales of $1.92 million. Conspicuously, that&rsquo;s 31.6% off the pace of last year&rsquo;s tally of $2.81 million. Still, the focal point is on fiscal 2025&rsquo;s projected sales of $13.34 million. Further, the high-side estimate lands at $42.88 million. Therefore, for the patient speculator, FULC could be one of the under-$10 biotech stocks to buy.</p>



<h2>CorMedix (CRMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/shutterstock_1726134715-300x169.png" alt="Biochemical/biotech research scientist team working with microscope"><div>Source: Mongkolchon Akesin / Shutterstock.com</div></div><p>Headquartered in Berkeley Heights, New Jersey, <strong>CorMedix</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/crmd-stock-quote/"><strong>CRMD</strong></a>) is a biopharma firm focusing on the development and commercialization of therapeutic products in the prevention and treatment of infectious and inflammatory diseases. Its lead product candidate is <a href="https://cormedix.com/cormedix-inc-announces-commercial-and-operational-updates/">DefenCath, an antimicrobial catheter lock solution</a> to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.</p>



<p>Although it&rsquo;s one of the riskiest under-$10 biotech stocks, it also enjoys plenty of love on the Street. Analysts rate shares a unanimous strong buy with a $12.67 price target. That implies upside potential of just under 117%. Also, the high-side target hits $19.</p>



<p>For fiscal 2024, experts are looking at a loss per share of 74 cents. That&rsquo;s still in the red but an improvement over last year&rsquo;s loss of 91 cents. On the top line, they&rsquo;re seeking $25.16 million. Last year, the company generated no revenue. Finally, for fiscal 2025, experts are seeking sales of $81.93 million, implying 225.6% YOY growth from projected 2024 revenue.</p>



<p><em>On the date of publication, Josh Enomoto</em><em> did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;</em><em>The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em><em></em></p>
<div><p>A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/biotech-on-a-budget-7-stocks-under-10-with-huge-potential/">Biotech on a Budget: 7 Stocks Under $10 With Huge Potential</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Biotech on a Budget: 7 Stocks Under $10 With Huge Potential

Justin Walsh, an analyst from JonesTrading, maintained the Buy rating on Actinium Pharmaceuticals (ATNM – Research Report). The associated price ta...

Actinium Pharmaceuticals: A Strong Buy on Regulatory Advances and Strategic Positioning

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Longeveron (LGVN – Research Report), Optinose (OPTN ...

Analysts' Top Healthcare Picks: Longeveron (LGVN), Optinose (OPTN)

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Actinium Pharmaceuticals</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/atnm-stock-quote/"><strong>ATNM</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Actinium Pharmaceuticals reported earnings per share of -31 cents. This was above the analyst estimate for EPS of -52 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/atnm-stock-earnings-actinium-pharmaceuticals-for-q1-of-2024/">ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024

B.Riley Financial analyst Yuan Zhi reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price target of...

Actinium Pharmaceuticals: A Strong Buy on the Horizon with Iomab-B's Potential and Strategic Growth Initiatives

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), wit...

Actinium Pharmaceuticals: A Strong Buy Amidst Radioligand Therapy Sector Growth and M&A Activity

Radiopharma stocks higher as sector welcomes the latest M&A deal

CASI

CLRB

CNTA

CRMD

FULC

FUSN

KPRX

LGVN

LNTH

MRNS

NVSEF

OCUL

OPTN

OTLK

RXRX

Press Releases

Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT's Innovative Clinical Trial

Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey

Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest

Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty

Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)

Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Actinium Pharma Stock (AMEX:ATNM), Short Interest Report

People Also Watch